Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder
Allergies · 2021
DOI: 10.3390/allergies1020007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergies, 2021. Verfasst von Misa Kusumoto und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a lack of prophylactic treatments and mechanistic understanding complicates efforts to prevent pathogenesis. This review will explicate and synthesize current knowledge on the effect of ACO and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) on pathogenesis, treatment, and prognosis.
Zitieren
APA
Kusumoto, M., & Mathis, B. J. (2021). Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder. Allergies. https://doi.org/10.3390/allergies1020007
Vancouver
Kusumoto M, Mathis BJ. Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder. Allergies. 2021. doi:10.3390/allergies1020007
BibTeX
@article{Kusumoto2021,
author = {Kusumoto, Misa and Mathis, Bryan J.},
title = {Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder},
journal = {Allergies},
year = {2021},
doi = {10.3390/allergies1020007}
}
EUVIMED